1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY DRUG CLASS
5.1. Introduction
5.2. Diuretics
5.3. Beta-Blockers
5.4. ACI Inhibitors
5.5. Calcium Channel Blockers
5.6. Combined Alpha and Beta-Blockers
5.7. Others
6. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY TYPE
6.1. Introduction
6.2. Primary Hypertension
6.3. Secondary Hypertension
7. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY SALES CHANNEL
7.1. Introduction
7.2. Prescription
7.3. Over-the-counter (OTC)
8. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Drug Class
8.2.2. By Type
8.2.3. By Sales Channel
8.2.4. By Country
8.2.4.1. USA
8.2.4.2. Canada
8.2.4.3. Mexico
8.3. South America
8.3.1. By Drug Class
8.3.2. By Type
8.3.3. By Sales Channel
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.2. Argentina
8.3.4.3. Others
8.4. Europe
8.4.1. By Drug Class
8.4.2. By Type
8.4.3. By Sales Channel
8.4.4. By Country
8.4.4.1. Germany
8.4.4.2. France
8.4.4.3. United Kingdom
8.4.4.4. Spain
8.4.4.5. Others
8.5. Middle East and Africa
8.5.1. By Drug Class
8.5.2. By Type
8.5.3. By Sales Channel
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.2. Israel
8.5.4.3. Others
8.6. Asia Pacific
8.6.1. By Drug Class
8.6.2. By Type
8.6.3. By Sales Channel
8.6.4. By Country
8.6.4.1. China
8.6.4.2. Japan
8.6.4.3. South Korea
8.6.4.4. India
8.6.4.5. Indonesia
8.6.4.6. Taiwan
8.6.4.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Boehringer Ingelheim International GmbH
10.2. DAIICHI SANKYO COMPANY, LIMITED
10.3. Novartis AG
10.4. Pfizer Inc.
10.5. Johnson & Johnson
10.6. Merck and Co. Inc.
10.7. Lupin Pharmaceuticals, Inc.
10.8. Sanofi S.A.
10.9. Sun Pharmaceutical Industries Ltd.
10.10. Bristol-Myers Squibb and Company